GemVax "GV1001 Demonstrates Effectiveness in Suppressing Chemotherapy Side Effects"

GemVax & Kael recently announced on the 15th that a paper elucidating the potential of GV1001 to prevent side effects of anticancer drugs was published in the SCI-level international journal related to cell and molecular biology, 'Cells' (IF 5.1).

Doxorubicin, used in various cancer treatments, is an effective anticancer drug but is known to cause serious side effects such as cardiovascular disease and atherosclerosis.

The study confirmed that GV1001 can prevent vascular damage caused by doxorubicin, reducing the side effects of anticancer treatment and improving the quality of life for cancer patients.

The research was conducted by a team at the UCLA School of Dentistry. Distinguished Professor No-Hee Park from UCLA School of Medicine and Dentistry and Advisor Sang-Jae Kim of GemVax participated as co-corresponding authors.

According to the paper, GV1001 effectively inhibited endothelial-mesenchymal transition (EndMT) caused by oxidative stress, inflammatory responses, and mitochondrial dysfunction induced by doxorubicin.

GV1001 reduced systemic and vascular inflammation, lipid accumulation, and macrophage infiltration caused by doxorubicin in apolipoprotein E (ApoE) deficient mice.

Although the effect of GV1001 in suppressing anticancer drug side effects was partially revealed in previous studies, this research clarified the specific mechanism and therapeutic potential.

The UCLA research team emphasized, "The study revealed the potential of GV1001 as a therapeutic agent that not only protects vascular endothelial cells but also suppresses lipid deposition in blood vessels, thereby reducing cardiovascular side effects such as atherosclerosis caused by doxorubicin."

According to the American Heart Association (AHA), cardiovascular disease has been the leading cause of death among Americans since 1920. The AHA projects that by 2035, approximately 45% of the U.S. population, or 131.2 million people, will suffer from cardiovascular disease.

A GemVax representative stated, "We have confirmed that GV1001 reduces serious side effects such as cardiovascular disease and atherosclerosis that occur during anticancer treatment," and added, "GV1001 presents a new adjuvant treatment option during anticancer therapy."